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Genomes of human cancer cells are character-
ized by numerous chromosomal aberrations of
uncertain pathogenetic significance. Here, in
an inducible mouse model of melanoma, we
characterized metastatic variants with an ac-
quired focal chromosomal amplification that
corresponds to a much larger amplification in
human metastatic melanomas. Further analy-
ses identified Nedd9, an adaptor protein re-
lated to p130CAS, as the only gene within
the minimal common region that exhibited am-
plification-associated overexpression. A series
of functional, biochemical, and clinical studies
established NEDD9 as a bona fide melanoma
metastasis gene. NEDD9 enhanced invasion
in vitro and metastasis in vivo of both normal
and transformed melanocytes, functionally
interacted with focal adhesion kinase and
modulated focal contact formation, and ex-
hibited frequent robust overexpression in hu-
man metastatic melanoma relative to primary
melanoma. Thus, comparative oncogenomics
has enabled the identification and facilitated
the validation of a highly relevant cancer
gene governing metastatic potential in human
melanoma.INTRODUCTION
Recurrent chromosomal structural aberrations are a hall-
mark feature of the human cancer genome and repre-
sent key pathogenetic events required for malignant
transformation (Hanahan and Weinberg, 2000; Storch-
ova and Pellman, 2004). The high resolution views af-
forded by current genome scanning platforms, such as
array-Comparative Genomic Hybridization (CGH), has
revealed presence of hundreds of recurrent focal copy
number alterations (CNAs) across diverse human can-
cers (Lucito et al., 2003; Aguirre et al., 2004; Tonon
et al., 2005; Zhao et al., 2005; Carrasco et al., 2006).
While providing unprecedented opportunities for cancer
gene discovery, this level of complexity has brought into
focus a critical need for biological systems capable of
culling bystanders and directing in-depth validation
efforts toward genomic alterations of prime disease
significance.
The melanoma genome exhibits a radically altered cy-
togenetic profile (Bastian et al., 2003). Deletion of 9p21
is a signature event that commonly targets p16INK4a and
ARF—each key regulator of the RB and p53 pathways, re-
spectively (Chin, 2003). The RAS-MAPK pathway is also
important in melanoma genesis, as evidenced by high-
frequency BRAF-activating mutations and less common,
yet reciprocal, NRAS-activating mutations (Davies et al.,
2002; Tsao et al., 2004; Chudnovsky et al., 2005). Recent
high-resolution genomic characterization has defined
many focal minimal common regions (MCRs) whichCell 125, 1269–1281, June 30, 2006 ª2006 Elsevier Inc. 1269
typically do not harbor known cancer genes, suggesting
that the known signature mutations likely represent only
a small fraction of the genetic events driving melanoma
development. That these genome events are targeting
genes of pathogenetic relevance is evident from the re-
cent identification of MITF, a lineage survival factor, as
the target of a focal amplification in melanoma (Garraway
et al., 2005).
While focal CNAs provide a tractable path to cancer
gene discovery, melanoma and other human cancers
also possess less informative, yet highly recurrent, chro-
mosomal gains and losses involving expansive regions.
A notable genomic event is chromosome 6p gain, which
is frequently observed in many cancer types, including
breast (Thompson et al., 1993), retinoblastoma (Lillington
et al., 2003), lymphoma (Stokke et al., 2001), NSCLC
(Tonon et al., 2005), multiple myeloma (Carrasco et al.,
2006), and others. In melanoma, 6p gain is observed in
over 35% of metastatic samples and cell lines but rarely
in primary melanoma (Bastian et al., 1998). The impor-
tance of chromosome 6p gain is reinforced by its associ-
ation with prognosis in a number of cancer types, such as
lymphoma, multiple myeloma, and melanoma (Lillington
et al., 2003; Namiki et al., 2005; Carrasco et al., 2006).
Thus, while high-resolution array-CGH has proven effec-
tive in delimiting high probability cancer gene candidates
within focal MCRs, there remains the daunting challenge
of target gene identification in these large regional gains
and losses.
Metastasis is a multistep process that requires and
selects for tumor cells capable of escaping their normal
microenvironment, traversing into and out of lymphatic
or blood vessels, and proliferating in new ‘‘soil’’ (Fidler,
2003). Implicit in these steps is a cell’s ability to migrate
and invade. Central to the processes of migration and
invasion is focal adhesion kinase (FAK), a nonreceptor
tyrosine kinase localized at the sites of integrin cluster-
ing and cell attachment to the extracellular matrix. The
nucleation of a FAK-CAS-Crk-DOCK180 complex is the
molecular signal for cell invasion (McLean et al., 2005).
FAK is activated through either intrinsic autophosphory-
lation in response to stimuli such as integrin engagement
or transphosphorylation by signals from growth factor
receptors of the Y397 residue. FAK Y397 phosphoryla-
tion produces a high-affinity binding site for association
with the SH2 domain of Src family kinase, which in turns
phosphorylates FAK on Y576, Y577, and Y861 residues,
creating an activated Src-FAK signaling complex capa-
ble of recruiting and activating a number of signaling
adaptors, in particular the CAS family adaptor protein,
p130Cas. Subsequent coupling of Crk to p130Cas is
the key molecular trigger for invasion and induces the
recruitment of DOCK180 complex and local activation
of RAC1. Localized RAC1 activity affects actin cytoskel-
eton remodeling and induces JNK activities to promote
MMP expression and extracellular matrix degradation
(McLean et al., 2005). Consistent with its central role
in invasion, FAK expression and/or activity have been1270 Cell 125, 1269–1281, June 30, 2006 ª2006 Elsevier Inc.reported to be elevated in a wide range of human malig-
nancies (thyroid, prostate, cervix, colon, rectum, oral ep-
ithelium, and ovary), particularly in advanced disease
and metastasis (McLean et al., 2005). However, evi-
dence that FAK or components of its complex are tar-
geted for activation on a genetic level (e.g., amplification
or activating mutation) in cancer and metastasis is still
lacking.
RESULTS
Identification of Genomic Events Associated
with Acquisition of Metastatic Potential
To deconvolute highly complex tumor genomes, we asked
whether cross-species genomic analyses of tumors of ge-
netically engineered mouse (GEM) models could provide
a biological filter for the identification of causal cancer
genes relevant to human melanoma biology. In an induc-
ible nonmetastatic melanoma model (Chin et al., 1999)
(Supplemental Data), through cycles of on and off trans-
gene expression, we generated 17 doxycycline-insensi-
tive escapers derived from four independent doxycy-
cline-sensitive melanoma cell lines (Figure 1A). Two of
these escapers showed no detectable RAS transgene ex-
pression, consistent with a genetic event enabling RAS-in-
dependent tumor growth. The remaining 15 escapers re-
tained RAS transgene expression in the absence of
doxycycline administration, consistent with a breakdown
in the inducible system. Escapers MK24 and MK25—
both derived from parental MK8 on opposing flanks of
a SCID mouse—expressed the RAS transgene (at compa-
rable level as parental MK8) in the presence or absence of
doxycycline (Figure S1A). While they both grew faster than
MK8 in subconfluent culture (Figure 1B; 2.5-fold relative to
MK8 on D4), only MK24 continued to proliferate beyond
confluency. In vivo, MK24-derived SQ tumors grew more
rapidly than its parental MK8 and metastsized to distal
sites (Figures 1C and S1B), leading to premature mortality.
In contrast, mice with MK8 parental tumor explants
showed no evidence of metastases or ill-health despite in-
creasing local tumor burden (data not shown). Consistent
with this metastatic behavior in vivo, MK24 cells exhibited
increased invasion into matrix protein in Boyden chamber
assay (Figure 1D; 4.2-fold compared to MK8, p = 0.046).
Interestingly, MK25 did not exhibit this invasive profile, in-
dicating that emergence of metastatic behavior is not
linked to breakdown of the inducible system. Another es-
caper, MK65, also shared this profile of increased meta-
static potential as MK24 (Figure 1). Therefore, we hypoth-
esized that MK24 and MK65 had acquired secondary
genetic/genomic event(s) that conferred this metastatic
capability.
To search for acquired genomic alteration(s) associated
with the metastatic variants, we performed genome-wide
array-CGH profiles (Experimental Procedures) of the es-
capers and their corresponding doxycycline-sensitive pa-
rental controls. Comparison of profiles of MK24 and its
parental MK8 readily revealed a novel amplification on
Figure 1. Characterization of Metastatic
Escapers
(A) For a description of the inducible system,
see Supplemental Data. Two illustrative paren-
tal tumors and their derivative doxycycline-in-
sensitive escapers were shown here. Note the
differences in latency for tumor formation, re-
gression kinetics, and number of transgene
on/off cycles required to generate escapers.
(B) Growth curves of parental tumor cell MK8
(on doxycycline) and its escaper derivative
lines, MK24, MK25, and MK65, in 1% serum-
containing media.
(C) Metastatic spread of MK24 on day 11 fol-
lowing subcutaneous injection. Note the mac-
roscopic nodules in intraperitoneal space, in-
cluding the diaphragm and uterine horn, at
time of dissection. See Figure S1B for micro-
scopic lesions.
(D) Increased in vitro invasion into matrix pro-
tein in Boyden chamber of escapers, MK24
and MK65, but not MK25, compared to paren-
tal MK8. Error bars correspond to standard de-
viation of replicate data points.chromosome 13, which was shared by MK65 (Figure 2A).
Boundaries of the MCR, which spans 850 kb (position
40.175 MB to 41.025 MB) with eight resident genes as
defined by array-CGH, were verified by genomic qPCR
(Figure S1C).
Next, we examined expression patterns of the 8 MCR
resident genes in 13 RAS-driven, 4 Met-driven mouse
melanomas and four independently derived primary
mouse melanocyte cultures (Figure 2B). The inclusion of
the Met-driven melanomas was intended to provide inde-
pendent validation of the metastases correlation since
Met-driven mouse melanomas were metastatic (data not
shown). Of the eight genes, only Nedd9 exhibited consis-
tent overexpression in samples with and without genomic
amplification when compared to nontransformed primary
melanocyte cultures (Figure 2B).
Amplification and Overexpression of NEDD9
in Human Metastatic Melanoma
To assess the relevance of NEDD9 in human melanoma,
copy number status of the syntenic locus on human chro-
mosome 6p25-24 was examined in a database of 610genome-wide array-CGH profiles of human solid tumors,
including 120 melanocytic lesions (nevi, primary, and
metastatic melanomas and cell lines). We observed that
6p25-24 sustains increased copy number in 36% of hu-
man metastatic melanomas and cell lines (23 of 63 and
12 of 35, respectively), compared with only 8% of primary
melanoma (2 of 25, p = 0.0009) and none of benign nevi
(0 of 10, p < 0.0001). To determine whether NEDD9 rep-
resents a target of 6p gains, we first asked whether
NEDD9 expression was upregulated in metastatic mela-
noma relative to nontransformed melanocytes. By RT-
qPCR, 50% of metastatic melanoma samples (10 of 20)
showed 10- to 70-fold overexpression of NEDD9 mRNA
relative to normal human melanocyte culture (FOM99)
(Figure S2A). Next, we compared NEDD9 protein expres-
sion on tissue microarrays (TMAs) containing 100 cores
each of metastatic melanoma and benign nevus speci-
mens. Using anti-NEDD9 monoclonal antibody (Figure S3
for E12 antibody specificity), we found that 52% of the
metastatic melanoma (51 out of the 98 informative cores)
showed significant protein expression above basal level
detected in 86% of the benign nevi (49 of 57 informativeCell 125, 1269–1281, June 30, 2006 ª2006 Elsevier Inc. 1271
Figure 2. Identification of Genomic
Events Associated with Metastatic Po-
tential
(A) Comparison of high-density array CGH pro-
files of parental MK8 and escaper MK24. Note
a high-amplitude focal amplicon and a gain of
whole chromosome 15 in MK24 but not in
MK8. Bottom panel shows the expanded view
of the bracketed region in two escapers,
MK24 and MK65, on mouse chromosome 13.
X-axis is shown in megabases.
(B) Expression analyses of MCR resident genes
by real-time qPCR relative to level in Ink4a/
Arf/ melanocytes (green triangles, n = 4).
Samples include tumors from Tyr/Tet-RAS
(red circles, n = 13) and Tyr/Tet-Met (Tyr-
rtTA+;Tet-c-Met+;Ink4a/Arf/; blue squares,
n = 4) mice with (one filled square and two filled
circles) or without (open squares and circles)
amplification of this region. Note consistent up-
regulation of Nedd9 expression in H-RASV12G
or c-Met driven mouse melanoma samples
with or without Nedd9 DNA copy number alter-
ation.cores) (Figure 3A; p < 0.0001). Therefore, NEDD9 is a can-
didate target of 6p gain in human melanoma as its expres-
sion is significantly upregulated relative to nontrans-
formed melanocytes and benign melanocytic neoplasia.
Since 6p gain is preferentially observed in metastatic,
but not primary, melanoma, we further asked whether
NEDD9 expression pattern correlated with progression.
Here, we conducted a second NEDD9 IHC study on a Mel-
anoma Progression TMA containing tumor specimens rep-
resenting the major diagnostic categories: benign nevi
(n = 35 cases), primary cutaneous melanoma (n = 60 cases),
and metastasis (75 cases), each with two to six indepen-
dent cores to offer a view of potential intratumoral hetero-
geneity. Each of the 480 cores was scored as 0–3+ based
on signal intensity in percentage of tumor cells (Experi-
mental Procedures). Each case was then assigned the
highest score from among its independent cores. In this
manner, we found that 35% of the metastatic melanoma
cases (26 out of 75) showed significant overexpression1272 Cell 125, 1269–1281, June 30, 2006 ª2006 Elsevier Inc.(3+) (Figures 3B and S3C), with the majority of them show-
ing broad rather than regional staining (e.g., all indepen-
dent cores for each sample reported the same scores;
data not shown). In contrast, only 5% of the primary mel-
anoma (3 of 60 cases) exhibited a similar level of 3+ ex-
pression (p < 0.0001 compared to metastatic melanoma).
Interestingly, 32 of 60 primary melanoma cases showed
2+ intermediate expression, while benign nevi cases rarely
scored above 1+ (Figure 3B), suggesting that NEDD9 ex-
pression may already be positively selected for even at the
primary melanoma stage prior to onset of metastasis. In
summary, protein expression surveys established that
NEDD9 overexpression correlates with metastatic pro-
gression in human melanomas.
RNAi-Mediated Nedd9 Knockdown Attenuates
Melanoma Metastatic Potential
Next, we assessed the impact of RNAi-mediated Nedd9
knockdown on proliferation and invasion of MK24 and
Figure 3. NEDD9 Is Overexpressed in
Human Metastatic Melanomas
Summary of two immunohistochemical sur-
veys of NEDD9 with E12 Ab (see Experimental
Procedures for details).
(A) NEDD9 is overexpressed in 52% of meta-
static melanoma and in 14% of nevi. Represen-
tative images of patchy expression in nevus
and strong and broad overexpression in mela-
noma are shown.
(B) NEDD9 overexpression is correlated with
melanoma progression. Representative im-
ages for 0+, 1+, 2+, and 3+ score of metastatic
melanomas are shown. See Figure S3C for rep-
resentative lower magnification views of pri-
mary and metastatic melanomas.MK65 escapers. Upon transduction of two lentiviral shRNA
vectors, shA and shB, which were documented to reduce
Nedd9 protein expression by 60% and 90%, respectively
(Figure 4A), MK24 and MK65 cells showed a potent 75%
to 50% or 25% reduction in macroscopic and microscopic
metastasis to distal sites (Table S1). The reduction in distal
metastasis in vivo prompted analysis of cellular prolifera-
tion and invasion in vitro. Knockdown of Nedd9 in MK24
decreased proliferation (Figure S4A) and inhibited invasion
in Boyden chamber by 30.8% for shA (p = 0.048) and
39.5% for shB (p = 0.023) relative to vector-infected cells
(Figure 4A; data not shown for MK65). In a metastatic mel-
anoma cell line, Malme3M containing B-RAFV600E muta-
tion and 20-fold upregulation of NEDD9 expression com-
pared to human melanocytes (data not shown), efficient
NEDD9 knockdown correlated with a significant inhibition
of invasion (Figure 4B; p = 0.029). Even in a nonmetastatic
UACC257 melanoma cell line with a low level of NEDD9expression, siRNA knockdown still reduced invasion in vitro
(Figure 4B; p = 0.083). Importantly, the impairment in inva-
sion that accompanied NEDD9 knockdown was observed
in context of unaffected and significant expression of
p130Cas (Figure 4B). In line with this,p130Cas knockdown
had marginal effect on cell cycle, whileNEDD9 knockdown
inhibited S phase progression (12.5% S phase for siNT ver-
sus 7.8% for siNEDD9 versus 11.7% for si-p130Cas) with-
out significant effect on apoptosis (Figure S4B). Together,
loss-of-function studies in mouse and human melanoma
cells support the view that continued NEDD9 expression
is vital for maintenance of invasive and metastatic potential
in melanoma cells.
NEDD9 Overexpression Confers Metastatic
Potential on Primary Melanocytes
To further substantiate a role for NEDD9 in metastases, we
next determined whether NEDD9 overexpression couldCell 125, 1269–1281, June 30, 2006 ª2006 Elsevier Inc. 1273
Figure 4. Loss of Function of Nedd9 Inhibits Invasion and Metastasis
(A) Nedd9 knockdown with two lentiviral shRNAs (shA and shB) in MK24 cells as documented by Western blot analysis with DF78 Ab (Figure S3A for
DF78 Ab) (top left) resulted in inhibition of invasion into matrix proteins in Boyden chamber when compared to empty vector infected cells (V).
(B) Human melanoma cell lines Malme3M and UACC257 were transfected with either nontargeting siRNA (siNT) or siRNA smart pool against NEDD9
(siNEDD9). Efficient knockdown of NEDD9 expression was achieved on both RNA (top left: 90% and 67% expression reduction by RT-qPCR for Mal-
me3M and UACC257, respectively) and protein (bottom left: Western blot with 2G9 Ab) levels and resulted in inhibition of invasion in Boyden cham-
bers (right: 40% and 57% for Malme3M and UACC257, respectively). Note unaffected p130CAS expression following efficient knockdown of NEDD9
expression in Malme3M and UACC257. Error bars correspond to standard deviation of replicate data points.confer metastatic potential on primary nontransformed
melanocytes (Supplemental Data). In three independent
primary Ink4/Arf/ melanocyte cultures, enforced
NEDD9 expression failed to enhance invasion or metasta-
sis in vitro or in vivo (Figure 5A and Table S2). Since MK24
and MK65 escapers retained a high level of RAS expres-
sion (Figure S1A) and the majority of human metastatic
melanomas harbor activated NRAS or BRAF mutations,
we hypothesized that NEDD9-mediated metastatic activ-
ity requires cooperative RAS pathway activation. Indeed,
enforced expression of NEDD9 in B-RAFV600E- or
H-RASV12-infected Ink4/Arf/ melanocytes (hereafter
designated as ‘‘M3-BRAF’’ or ‘‘M3-HRAS’’) enhanced in-
vasion in Boyden chamber by 3.4-fold (p = 0.0013) and
2.3-fold (p = 0.0097), respectively (Figure 5A), comparable
to the effect of p130Cas activation (Figure S5). In vivo,
combined expression of NEDD9 and oncogenic H-RASV12
or B-RAFV600E dramatically increased lung seeding of
Ink4a/Arf/ melanocytes from 3.8% to 20% (p = 0.0025)1274 Cell 125, 1269–1281, June 30, 2006 ª2006 Elsevier Inc.and 10% to 54% (p < 0.001), respectively (Figure 5B and
Table S2).
On the other hand, proliferation was also enhanced by
NEDD9 overexpression in vivo and in vitro (Figures 5C
and S6 and Table S3), raising the possibility that the in-
vasive and metastatic phenotypes associated with its ac-
tivation were consequences of increased proliferation. To
address this, we compared the invasion profiles of thymi-
dine-arrested (Zielke and Littlefield, 1974) and proliferating
M3-HRAS melanocytes (Figure S7) in Boyden Chamber
assay. As shown in Figure 5D, enforced NEDD9 expression
similarly enhanced matrix invasion by 3.12-fold (p = 0.113)
and 3.65-fold (p = 0.043) in cycling and noncycling melano-
cytes, respectively. In other words, NEDD9 possesses
intrinsic proinvasion activity, which is independent of its
effects on the cell cycle.
Lastly, to assess whether NEDD9 activation repre-
sented the seminal and sufficient genetic event conferring
metastatic behavior in MK24 and MK65 escapers, we
Figure 5. Gain of Function of NEDD9 Pro-
motes Invasion and Metastasis
(A) Boyden chamber assays. NEDD9 in con-
junction with H-RASV12G or B-RAFV600E ex-
pression in M3 Ink4a/Arf/ melanocytes en-
hanced invasion through matrix proteins, but
NEDD9 by itself had no effect on invasion
(left). Fold increase of invasion by NEDD9 com-
pared to vector infected cells is shown with p
values (Student’s t test).
(B) Lung seeding assays. Right panels show
H&E stained lung sections derived from SCID
mice injected with vector or NEDD9-express-
ing Ink4a/Arf/ melanocytes (top: M3-HRAS;
bottom: 3B3-BRAF) via tail veins. Degree of
lung seeding was quantitated as % tumor re-
placement of lung parenchyma on H&E (left)
(see Table S2 for summary).
(C) Growth curve of M3-HRAS cells with empty
vector or with NEDD9 in 1% serum-containing
media over 8 days.
(D) Comparable increase in invasion through
matrix protein in Boyden chamber by NEDD9
expression in cycling and noncycling M3-
HRAS melanocytes. See Figure S6 for sche-
matic and cell-cycle profiles. Error bars corre-
spond to standard deviation of replicate data
points.monitored metastatic activity following NEDD9 transduc-
tion into nonmetastatic parental cells, MK8, with reconsti-
tuted H-RASV12G expression (hereafter ‘‘MK8-HRAS’’). In-
deed, NEDD9-expressing MK8-HRAS cells enhanced
invasion in Boyden chamber (data not shown) and re-
sulted in dramatic obliteration of the lungs with tumor nod-
ules following tail-vein injection (Figure S8A; 63% versus
12%; p < 0.0001). In summary, these in vitro and in vivo
gain-of-function studies showed that NEDD9, in coopera-
tion with RAS-RAF signaling, is capable of enhancing met-
astatic potential of primary nontransformed melanocytes
and nonmetastatic melanoma cells.
NEDD9 Requires Focal Adhesion Kinase for Invasion
To glean mechanistic insight into NEDD9’s role in invasion
and metastasis, we surveyed potential links between
NEDD9 and signaling molecules of known relevance to
tumor invasion and metastasis. NEDD9 overexpression
had little or no effect on many key molecules, stimulating amoderate 3-fold increase in ERK phosphorylation only in
M3-HRAS melanocytes and a small 1.7-fold Stat3 activa-
tion in M3-BRAF melanocytes (Figure 6A and Table S4).
The one notable and consistent NEDD9-induced alteration
in both M3-HRAS and M3-BRAF melanocytes was robust
activation of FAK (Y397-phosphorylation) by 28- to 70-fold
(Figure 6A, lanes 2 and 3). Furthermore, such NEDD9-in-
duced FAK activation was observed only with concomitant
RAS/RAF signaling. The molecular link of NEDD9 to FAK
activation was reinforced by loss of FAK Y397 phosphory-
lation upon RNAi-mediated NEDD9 knockdown in MK24
and Malme3M melanoma cells (Figure 6B).
The profile of FAK activation suggested that NEDD9
might function via focal adhesion signaling. Thus, we as-
sessed whether FAK was required for NEDD9-induced
invasion in Boyden chamber. To this end, two indepen-
dent shRNAs against FAK (shFak1 and shFak2) and
a parental-vector hairpin control (shNT) was separately
transduced into NEDD9-expressing M1-HRAS, M3-HRAS,Cell 125, 1269–1281, June 30, 2006 ª2006 Elsevier Inc. 1275
Figure 6. NEDD9 Activates and Functionally Requires FAK
(A and B) Western blot analysis of cell lysates with antibodies indicated. Ectopic expression of NEDD9 in melanocyte (A) was detected with Flag Ab,
and endogenous Nedd9 in MK24 and NEDD9 in Malme3M (B) were detected with DF78 Ab and 2G9 Ab, respectively.
(C) FAK expression was knocked down with two independent shRNAs against FAK (shFak1 and shFak2), and decreased FAK expression in M3-HRAS
and MK8-HRAS was confirmed by Western blot (bottom). Top panels show relative invasion of NEDD9-expressing cells with or without FAK knock-
down compared to cells with empty vector in Boyden chamber assay, showing increased invasion through matrix protein by NEDD9 expression
compared to vector, which was reversed by loss of FAK expression in M3-HRAS and MK8-HRAS cells. Error bars correspond to standard deviation
of replicate data points.or MK8-HRAS cells. Upon documentation of FAK knock-
down on protein level (Figure 6C and data not shown),
relative invasion normalized to M3-HRAS or MK8-HRAS
cells without NEDD9 (Empty Vector, EV) was measured
in Boyden Chamber. Indeed, while NEDD9 expression
increased the invasion of M3-HRAS melanocytes by 2.6-
fold, FAK knockdown completely reversed this enhance-
ment (Figure 6C) without affecting cell viability (Figure S9).
Similar effect was observed with MK8-HRAS cells in vitro,
while shFak-transduced MK8-HRAS cells were selected
against in vivo, leading to robust reactivation of Fak ex-
pression in lung seeding (Figure S8B). In addition, distal
macroscopic liver metastasis after tail-vein injection of1276 Cell 125, 1269–1281, June 30, 2006 ª2006 Elsevier Inc.M1-HRAS melanocytes was reduced from 100% in
shNT control to 0% and 50% of shFak1 and shFak2 co-
horts, respectively (data not shown). Taken together,
these knockdown studies pointed to functional require-
ment for FAK in NEDD9’s role in invasion and metastasis.
NEDD9 Modulates Focal Contacts Formation
Since NEDD9 functionally requires FAK for invasion and
metastasis, we asked whether NEDD9 colocalizes with
p-FAK to sites of and modulates the formation of focal con-
tacts, a dynamic form of cell adhesion structures required
for migration and invasion. Here, we performed coimmu-
nofluorescence (co-IF) in M3-HRAS melanocytes with
and without NEDD9 expression. While focal contacts were
rarely observed in vector-control melanocytes, NEDD9
overexpression significantly induced the formation of focal
contacts: NEDD9 (red) and p-Fak (blue) colocalized to cell
adhesion structures (purple) enriched for Paxillin and Crk
(white arrows) (Figures 7A and S10). Similarly, colocaliza-
tion of endogenous NEDD9 and p-FAK was demonstrated
in Malme3M human metastatic melanoma cells at protrud-
ing edges (Figure 7B). Importantly, siRNA knockdown of
NEDD9 effectively eliminated these focal contacts, result-
ing in retraction of cell body and loss of attachment without
affecting cell viability (Figure S4B).
Finally, to functionally demonstrate that the cell adhe-
sion structures promoted by NEDD9 are focal contacts,
we showed that NEDD9 expression enhanced cell attach-
ment within 15 min (Disatnik and Rando, 1999) (Figure 7C),
which is mediated by transient dynamic adhesion struc-
tures (e.g., focal contacts) rather than by the more stable
mature focal adhesions known to inhibit, rather than en-
hance, movement. Again, this effect of NEDD9 in the tran-
sient attachment assay was abolished by FAK knockdown
(Figure 7C). Together, these studies indicated that NEDD9
interacts with FAK to modulate formation of focal contacts
to enhance invasion.
DISCUSSION
Here we have exploited the experimental merits of an in-
ducible mouse model of melanoma, combined with
high-resolution genomic analysis, to identify metastatic
variants and their associated genotypic alterations. We
have provided genetic, functional, and mechanistic evi-
dence of a prominent role for NEDD9 in melanoma meta-
static potential and have translated these observations to
human clinical material and melanoma cell culture
models. In addition, this study has illustrated the utility of
GEM models and comparative oncogenomics as a filter
to mine complex human cancer genomes for clinically rel-
evant mutational events.
NEDD9 Enhances Melanoma Metastasis
Nedd9 (Neural precursor cell expressed, developmentally
downregulated 9), also known as HEF1, was initially iden-
tified by its developmentally regulated expression pattern
in the brain (Kumar et al., 1992). Structural relatedness
places Nedd9 in the CAS family of adaptor molecules
that includes p130Cas and Efs/Sin (O’Neill et al., 2000).
Like p130Cas, NEDD9 is localized to focal adhesions in
HeLa and NIH3T3 cells (Law et al., 1996) and regulates
spreading and migration of Jurkat T cells and MCF7 cells
(O’Neill and Golemis, 2001; van Seventer et al., 2001).
NEDD9 also regulates Aurora A and Nek2 in centrosome
cohesion and amplification to coordinate cell attachment
and cell division (Pugacheva and Golemis, 2005). Here,
NEDD9 is shown to be targeted for activation in melanoma
and functions to enhance metastasis in vivo.
Mechanistically, the model of focal adhesion dependent
invasion mediated by activation of and signaling from theFAK-CAS-Crk-DOCK180 complex (McLean et al., 2005)
fits our data on NEDD9 function in melanoma. Specifically,
NEDD9 colocalizes with p-FAK and Crk to dynamic focal
contacts in cell periphery. In line with FAK-CAS-Crk cou-
pling being the key molecular switch for invasion,
NEDD9 physically interacts with p-FAK and Crk (Fig-
ure S11 and data not shown). Functionally, NEDD9 re-
quires FAK as RNAi-mediated knockdown of FAK abol-
ishes NEDD9-induced invasion and metastasis in vitro
and in vivo. Accordingly, NEDD9 overexpression or
knockdown leads to increase or decrease, respectively,
in number and size of focal contacts. It has been shown
that even in face of elevated FAK RNA and protein level,
suppression of p130Cas and consequently reduced
p130Cas-Crk coupling could prevent the activation of
FAK, which was reversible by overexpression of
p130Cas (Zhang et al., 2003). Therefore, our data suggest
that the biological impact of NEDD9 amplification and
overexpression in melanoma is the activation of FAK-
CAS-Crk-DOCK130 complex at focal contacts.
Importance of FAK signaling in cancer has gained in-
creasing recognition, and recent reports have experimen-
tally implicated FAK activation in melanoma progression.
In a 3-D culture model system, it was shown that disrup-
tion of FAK signaling by expression of FAK-related non-ki-
nase (FRNK) led to reduction in invasion, migration, and
vasculogenic mimicry potential of aggressive melanoma
cells (Hess et al., 2005; Hess and Hendrix, 2006). In the Xi-
phophorus melanoma system, oncogenic receptor Xmrk
(ortholog of epidermal growth factor receptor) interacted
with FAK and increased turnover of focal adhesions
(Meierjohann et al., 2006). In a syngeneic rat model, FAK
was required for in vivo metastasis (van Nimwegen et al.,
2005). Mda-9/syntenin (Melanoma differentiation associ-
ated gene-9), a positive regulator of melanoma metasta-
sis, colocalized with phosphorylated FAK at cell margins
and increased FAK phosphorylation with activation of
JNK and p38 (Boukerche et al., 2005). However, genetic
evidence that component(s) of the focal adhesion com-
plex can be directly targeted for activation in cancer has
not been described. Hence, this study is the first to dem-
onstrate evolutionary conserved genomic activation of
a component of the focal adhesion complex, NEDD9, dur-
ing melanoma metastasis, pointing to inhibition of this sig-
naling complex as potential means to halt progression of
primary melanoma to metastatic disease.
NEDD9 in Development and Cancer
As melanocytes are neural crest derivatives that possess
an inherent ability to migrate to distant locations during
development, it has been proposed that such migratory
capabilities may be related to the propensity of melanoma
to metastasize as it reacquires an earlier state of differen-
tiation (Gupta et al., 2005). Indeed, an intimate link be-
tween differentiation state and metastasis has been
forged by observation that melanocyte developmental
transcription factors—Twist (Hoek et al., 2004; Yang
et al., 2004), Slug (Gupta et al., 2005), and MITF (GarrawayCell 125, 1269–1281, June 30, 2006 ª2006 Elsevier Inc. 1277
Figure 7. NEDD9 Colocalizes with FAK
and Enhances Dynamic Focal Contact
Formation
(A) NEDD9 is colocalized with p-FAK (Y397) at
focal contacts (arrows) in the cell periphery of
melanocytes (purple spots). Number and size
of focal contacts was small in EV melanocytes
with a low level of endogenous Nedd9 expres-
sion. Overexpression of NEDD9 increased the
size and number of focal contacts, which
were adhesion structures enriched by Paxillin
and Crk (also see Figure S10). Both endoge-
nous and exogenous NEDD9 proteins are de-
tected with 2G9 Ab.
(B) Endogenous colocalization of p-FAK (Y397)
and NEDD9 was observed in human Malme3M
melanoma cells (yellow/orange spots), which
was dramatically reduced by NEDD9 knock-
down (siNEDD9), resulting in retraction of cell
body and detachment without, however, in-
ducing apoptosis (see Annexin V FACS in
Figure S4B, performed on same batch of cells).
(C) Transient attachment assays. Ectopic ex-
pression of NEDD9 in M3-HRAS melanocytes
increased cell attachment onto matrigel com-
pared to EV control within 15 min, which was
reversed by loss of FAK expression. Error
bars correspond to standard deviation of repli-
cate data points.et al., 2005)—play critical roles in the metastatic progres-
sion of melanoma. In this regard, it is intriguing that
NEDD9 is expressed in neural precursor and that its ex-
pression is downregulated in development (Kumar et al.,
1992), raising the possibility that NEDD9 may be the rele-
vant CAS family member involved in melanocyte precur-
sor migration during development, and NEDD9 represents
yet another example of an embryonic differentiation pro-
gram gone awry in cancer.
Bernards and Weinberg have proposed that genes in-
volved in metastatic progression likely play a role in tumor
growth, for such growth advantage is necessary for clonal
selection of rare tumor cells competent for metastasis
(Bernards and Weinberg, 2002). Indeed, that is the case
for NEDD9, which has dual, but separable and distinct,
roles in proliferation and invasion. The observation that
53% of human primary melanoma specimens already
showed higher NEDD9 expression relative to benign nevi
suggested a selection for NEDD9 prior to metastasis
and a possibility that NEDD9 amplification or overexpres-
sion in a regional/focal manner may identify a subset of1278 Cell 125, 1269–1281, June 30, 2006 ª2006 Elsevier Inc.primary melanoma tumors with increased risk of metasta-
sis. In this regard, it is of particular relevance that NEDD9
is included in the 18-gene signature predictive of lung me-
tastasis in breast adenocarcinoma (Minn et al., 2005).
However, the prognostic significance of NEDD9 in primary
melanoma will require rigorous investigation and valida-
tion in appropriately designed prospective clinical trials.
Comparative Oncogenomics to Mine the Highly
Complex Human Cancer Genomes
Evolution preserves molecular mechanisms governing bi-
ological processes. Thus, it is reasonable to assume that
overlapping genomic events in mouse and human tumors
would represent critical genetic events shaped by biolog-
ical pressures during tumor genesis and progression. In-
deed, it has been shown that many of the acquired geno-
mic events in GEM model are syntenic to alterations in the
equivalent human tumor type (O’Hagan et al., 2002).
Therefore, comparison of GEM and human tumors pro-
vides a productive approach for identification of con-
served genetic events of biological importance. This study
substantiates this view as the existing human oncoge-
nomic data alone would not have readily revealed
NEDD9 as a key melanoma metastases gene.
While recurrence and correlation with prognosis speak
to importance of 6p gain in multiple cancer types, the ex-
pansive nature of this genomic alteration has hampered
the search of clinically relevant target(s). The emergence
of a recurrent focal amplification in two independent
GEM models of metastatic melanoma pinpointed
NEDD9 as a candidate target of 6p gain in melanoma.
However, the large regional alteration and lack of occa-
sional focal event despite high recurrence likely indicate
the presence and synergistic activities of multiple onco-
genes on 6p besides NEDD9.
This study also highlights another significant advantage
of cancer gene discovery and validation in GEMs, namely
the relative ease of establishing firm genotype-phenotype
correlations in the mouse, for such insight can guide the
intelligent design of validation assays. In this case, the
connection of Nedd9 amplification with metastasis led to
our focus on invasion assays. When confronted with the
lack of activity in primary melanocytes without oncogene
activation, the genetic context in which these metastatic
escapers emerged was instructive in defining the appro-
priate background (e.g., cooperating HRAS or BRAF on-
cogenic activation) against which activities of Nedd9
could be assessed.
Embedded within the highly rearranged and altered
cancer genomes are both driver and passenger events.
Large-scale characterization of cancer will most certainly
identify both types of changes. Therefore, it will be neces-
sary to prioritize likely causal alterations since significant
time and human investments are necessary to functionally
validate, mechanistically define, and ultimately enlist into
drug discovery candidates for targeted therapies. Given
the complexity of the cancer genomes as uncovered by
recent genome-wide characterizations, which likely repre-
sents only a fraction of the cancer gene atlas, the chal-
lenge of culling the bystanders from these causal alter-
ations will remain daunting. Robust, stringent, and
biologically relevant systems for filtering, annotating, and
prioritizing the efforts of cancer geneticists and biologists
will be essential to facilitate and accelerate the translation
of our genomic knowledge into cancer drugs that will im-
pact patient survival. This has illustrated the power of the
GEM models as one such system.
EXPERIMENTAL PROCEDURES
In Vitro Assays
Melanocytes and melanoma cells were transduced with pLZRSD-
IRES-GFP (Kinsella and Nolan, 1996), pLZRSDNEDD9-IRES-GFP,
pRevTre (Clontech)-H-RASV12G, or pRevTre-B-RAFV600E for ectopic
expression. SMARTpool siRNAs against NEDD9 or p130CAS was pur-
chased from Dharmacon, and lentiviral based shRNA constructs
against mouse Nedd9 (shA: CCTACCAGAATCAGGGAATTT, shB: CC
CACCAGATTCTAAGCCAAA), Fak (shFak1: CCTGGCATCTTTGATAT
TATA, shFak2: GACAGATGACTATGCAGAGAT) were obtained fromDFCI-Broad RNAi Consortium in pLKO.puro vector. For experimental
details on transduction and culture condition, see Supplemental Data.
Cell invasion assays were performed in Boyden chamber with matrix
proteins as per manufacturer’s protocol (BD biosciences). Data was
normalized with the ratio of input cells, grown for the same length of
time to control for cell proliferation rate. Statistical analysis was per-
formed with Student’s t test.
For transient attachment assays, cells were seeded in triplicate in 1%
serum-containing media at 43 104 cells per well in 96 well plates, pre-
coated with matrigel, and blocked with BSA. Following 15 min of incu-
bation, attached cells were fixed following vigorous washes with PBS,
stained with crystal violet, and quantitated by measuringO.D. at 595 nm.
Array CGH Profiling on cDNA and High-Density Oligonucleotide
Microarrays
All samples (four parental samples and 11 escapers) were profiled on
mouse cDNA microarray containing 10260 cDNA clones (Agilent Tech-
nologies, Mouse cDNA clone set) (Aguirre et al., 2004; Brennan et al.,
2004) with median interval of 79.57 kilobases (kb) between mapped
elements. To better define the boundaries, two samples with focal am-
plification on chromosome 13 (MK24, MK65) and parental MK8 were
reprofiled on a tiling-path CGH array (Nimblegene Systems, Inc.)
with a minimum probe spacing of 4.5 kb (Singh-Gasson et al., 1999).
See Supplemental Data for details.
Immunoblotting and Immunofluorescence
Western blots were probed with antibodies against AKT, phospho(p)-
AKT (Ser473), Erk, p-Erk, Stat3, and p-Stat3 (705) from Cell Signaling
Technology; FAK and p130CAS from BD Transduction Laboratories;
p-Fak (397) from Biosource; and Flag and b-Tubulin from Sigma.
For immunofluorescent staining, cells were grown on matrigel-
coated chamber slides, fixed with 4% paraformaldehyde, and stained
with anti-NEDD9 (2G9, Abcam), p-FAK (Y397, Biosource), Paxillin (BD
Transduction Laboratories), and Crk (BD transduction laboratories) an-
tibodies. Secondary antibodies used are Cy3-conjugated goat anti-
mouse IgG (H+L) and FITC-conjugated goat anti-rabbit IgG (H+L)
(Jackson immunoresearch) and Alexa Fluor 350 F(ab0)2 goat anti-rab-
bit IgG (H+L) (Molecular probe).
Lung Seeding Assays and SCID Explant Tumors
MK24 and MK65 were implanted in flanks of CB-17-scid (C.B-Igh-1b/
IcrTac-Prkdcscid; Taconic) mice at 7 3 105 cells/site subcutaneously,
and tumors were allowed to develop for 11 days. Major organs and
SQ tumors were harvested for histological analyses. Melanocytes of
different genotypes (H-RASV12G, B-RAFV600E, and NEDD9) were in-
jected through tail vein of CB-17-scid at 2.5 3 105 cells/mouse for
M3, M1, and MK8 and 53 105 cells/mouse for C140 and 3B3. Degree
of lung seeding was determined by lung:body weight ratio at necropsy
and by histopathological scoring of percentage of normal lung paren-
chyma replacement with infiltrating tumor nodules by S.R.G. in
a blinded manner. These melanocytes were also implanted subcuta-
neously into SCID mice at 1 3 106 cells/site, and tumors collected at
the indicated time were weighed at the time of dissection. The p value
was calculated with Student’s t test.
Human TMA-IHC Studies
E12 mouse monoclonal antibody was generated by DFCI Hybridoma
Core Facility against N-terminal fragment (aa 82-359) of human
NEDD9. NEDD9 IHC was performed on TMA with heat-induced epi-
tope retrieval (0.01M citrate buffer, pH6.0), labeled StreptAvidin Biotin
(LSAB) -Alkaline Phosphatase detection, and NovaRed (Vector lab) vi-
sualization. E12 Ab was incubated on TMA for 2 hr at room tempera-
ture without dilution.
Nevi-Melanoma TMA: The Nevi-Melanoma TMA consists of four
glass slides, each 50 cores, containing a total of 100 cases of benign
nevi (congenital, acquired, Spitz, and dysplastic) and 100 cases of
metastatic melanoma (lymph node, skin, brain, intestinal, liver, andCell 125, 1269–1281, June 30, 2006 ª2006 Elsevier Inc. 1279
lung). Cases were selected from the archive of MGH Department of
Pathology. Immunostaining for each core was scored from 0+ to 3+
in a blind fashion by SRG: 0+ showed no staining; 1+ showed weak
staining; 2+ showed moderate staining; and 3+ showed strong stain-
ing. Basal expression group includes samples with a 0+ or 1+ score,
and overexpression group contains samples with a 2+ or 3+ score
for NEDD9 expression. The p value was calculated by Student’s t test.
Progression TMA: The Melanocytic Progression TMA produced
jointly by three Skin SPORES (Harvard, MD Anderson, U Penn) con-
tains 4803 0.6mm cores of tissues corresponding to 240 distinct his-
tological regions in duplicate from 170 cases: 130 cores from 35 nevi,
200 cores from 60 primary melanoma, and 150 cores from 75 meta-
static lesions. Multiple cores from the same samples are chosen
from histopathologically distinct regions of a specimen to represent in-
tratumoral heterogeneity. Statistically, this TMA is designed to detect
event frequency greater than 5%. The intensity of signal was deter-
mined through visual inspection through microscope by L.M.D. and
scored as follow: 0 for no staining and no background; 1+ for weak
blush of cytoplasmic staining in more than 25% of cells or moderately
intense granular cytoplasmic staining in fewer than 25% of tumor cells;
2+ for moderately intense granular cytoplasmic staining in more than
25% of cells but without intense staining in some cells; and 3+ for gran-
ular cytoplasmic staining in more than 25% of tumor cells with mark-
edly intense cytoplasmic staining. All cases had two to six replicate
cores for scoring. Each case was assigned the highest score from
among its independent cores. Statistical analysis was performed by
Student’s t test.
Supplemental Data
Supplemental Data include eleven figures, four tables, and Experimen-
tal Procedures and can be found with this article online at http://www.
cell.com/cgi/content/full/125/7/1269/DC1/.
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